Dg. Bailey et al., Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients, CLIN PHARM, 68(5), 2000, pp. 468-477
Objectives: To determine whether unprocessed grapefruit can cause a drug in
teraction, whether the active ingredients are naturally occurring, and whet
her specific furanocoumarins or flavonoids are involved.
Methods: The oral pharmacokinetics of felodipine and its dehydrofelodipine
metabolite were determined after administration of felodipine 10 mg extende
d-release tablet with 250 mt commercial grapefruit juice, homogenized grape
fruit segments, or extract of segment-free parts equivalent to one unproces
sed fruit or mater in a randomized four-way crossover study. Inhibition of
recombinant CYP3A4 by furanocoumarins (bergamottin, 6',7'-epoxybergamottin,
6',7'-dihydroxybergamottin) and flavonoids (naringenin optical isomers) wa
s determined. Furanocoumarin and naringenin precursor (naringin) concentrat
ions were measured in each grapefruit treatment,
Results: Felodipine AUC with commercial grapefruit juice, grapefruit segmen
ts, or grapefruit extract was on average 3-fold higher than that with water
. Felodipine peak concentration was higher, but the half-life was unchanged
, The dehydrofelodipine/felodipine AUC ratio was reduced. The furanocoumari
ns produced mechanism-based and competitive inhibition of CYP3A4, Bergamott
in was the most potent mechanism-based inhibitor. Naringenin isomers produc
ed only competitive inhibition. Bergamottin, 6',7'-dihydroxybergamottin, an
d naringin concentrations varied among grapefruit treatments but were suffi
cient to inhibit markedly in vitro CYP3A4 activity.
Conclusions: Unprocessed grapefruit can cause a drug interaction with felod
ipine, The active ingredients are naturally occurring in the grapefruit. Be
rgamottin is likely important in drug interactions with commercial grapefru
it juice. 6',7'-Dihydroxybergamottin and naringin may be more important in
grapefruit segments because they are present in higher concentrations. Any
therapeutic concern for a drug interaction with commercial grapefruit juice
should now be extended to include whole fruit and possibly confectioneries
made from grapefruit peel.